Management of advanced prostate cancer

Oncologist

Volumn 5, Issue 1, 2000, Pages 36-44

  Auclerc, Gerard ^a,b   Antoine, Eric C ^a   Cajfinger, Francis ^a   Brunet Pommeyrol, Arlette ^b   Agazia, Chahrok ^b   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre Charlebourg   (France)

Author keywords

Advanced prostate cancer; Chemotherapy; Hormonal therapy; Hormone resistance; Irradiation; Quality of life evaluation

Indexed keywords

ALPHA2A INTERFERON; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIANDROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; CYTOTOXIC AGENT; DIETHYLSTILBESTROL; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ESTROGEN; FLUTAMIDE; FOSFESTROL; GONADORELIN DERIVATIVE; HYDROCORTISONE; LETROZOLE; LIAROZOLE; LIOPROZOLE; MEGESTROL ACETATE; MITOXANTRONE; PAMIDRONIC ACID; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG; VINBLASTINE;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; HORMONE SENSITIVITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT PLANNING;

EID: 0034100127     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-1-36     Document Type: Article

References (54)

1. Petrovich Z, Baert L, Bagshaw MA et al. Adenocarcinoma of the prostate: innovations in management. Am J Clin Oncol 1997;20:111-119.
2. Parker SL, Tong T, Bolden S et al. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
3. Richard F. Epidémiologie du cancer de la prostate et ses implications en santé publique. Rev Prat 1994;44:575-579.
4. Landis SH, Murray T, Bolden S et al. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
5. Dawson NA. Treatment of progressive metastatic prostate cancer. Oncology 1993;7:17-24.
6. Scher HI. Cytotoxic chemotherapy for advanced prostate cancer: does it work, and if no, how do we prove it? In: Perry MC, ed. Educational Book, 34th Annual Meeting ASCO; May 16-19, 1998. Los Angeles, CA, 1998:356-367.
7. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15:382-388.
8. Crawford ED, Bennett CL, Stone NN et al. Comparison of perspectives on prostate cancer: analysis of survey data. Urology 1997;50:366-372.
9. The Medical Research Council Prostate Cancer Working Party Investigators Group: immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235-246.
10. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effects of castration, of œstrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
11. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veteran's Administration Cooperative Urological Research Group Studies. Natl Cancer Inst Monogr 1988;7:165-170.
12. Grise P, Mnif A, Navarra S et al. Traitement par ST52 du cancer de la prostate au stade d'échappement hormonal. Ann Urol 1998;32:39-44.
13. Dahllof B, Billstrom A, Cabral F et al. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 1993;53:4573-4578.
14. Tew KD, Stearns ME. Hormone independent nonalkylating mechanism of cytotoxicity for estramustine. Urol Res 1987;15:155-160.
15. Blackledge G, Kolvenbag G, Nash A. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Anticancer Drugs 1996;7:27-34.
16. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
17. Denis LJ, Whelan P, Carnerio De Moura JLC et al. Goserelin acetate and flutamide versus bilateral orchidectomy: a phase III EORTC Trial (30853). Urology 1993;42:119-130.
18. Crawford ED, Eisenberger MA, McLeod DG et al. Comparison of bilateral orchidectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: results of NCI intergroup study 0105 (SWOG and ECOG). J Urol 1997;157:336a.
19. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-269.
20. Crawford ED, Stenner J, Rosenblum M. Changing concepts in hormonal therapy. Cancer Invest 1998;16(suppl 1):60-62.
21. Limonta P, Dondi D, Moretti RM et al. Antiproliferative effects of luteinizing hormone-releasing hormone agonist on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992;75:207-212.
22. Caubel JF, Tosteson TD, Dong EW et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using non steroidal antiandrogens. Urology 1997;49:71-78.
23. Schellhammer P, Sharifi R, Block N et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind randomized multicenter trial. Urology 1997;50:330-336.
24. Akakura K, Bruchovsky N, Goldenberg SL et al. Effects of intermittent androgen suppression on androgen dependant tumors. Cancer 1993;71:2782-2790.
25. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen receptor gene in metastatic androgen independant prostate cancer. N Engl J Med 1995;332:1393-1398.
26. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplication of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-405.
27. Bruchovsky N, Rennie PS, Coldman AJ et al. Effects of androgen withdrawal on the stem cell composition of the shionogi carcinoma. Cancer Res 1990;50:2275-2282.
28. Kelly WK, Scher HJ. Prostate specific antigen decline after antiandrogen withdrawal. The flutamide withdrawal syndrome. J Urol 1993;149:607-609.
29. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566-1572.
30. Berry WR, Laszlo J, Cox E et al. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 1979;44:763-775.
31. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995;46:142-148.
32. Eisenberger MA, Abrams JS. Chemotherapy for prostatic cancer. Semin Urol 1988;6:303-310.
33. Yagoda A. Cytotoxic agents in prostate cancer: an enigma. Semin Urol 1983;1:311-321.
34. Collste LG. Second line treatment of hormone refractory prostatic cancer patients. EORTC Genito-urinary Groupe Monograph 1990;7:29-39.
35. Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer 1993;71:1089-1093.
36. Matzkin H, Soloway MS. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma. Urology 1992;40:78-80.
37. Kristiansen P, Bergquist D, Janzon L et al. Thromboembolic side effects of diethyl stilbestrol diphosphate in patients with prostatic carcinoma. Urol Int 1988;43:44-46.
38. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;15:996-1004.
39. Tannock IF, Gospodarowicz M, Meakin W et al. Treatment of metastatic prostate cancer patients with low dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590-597.
40. Ellerhorst JA, Tu S, Amato RJ et al. Phase II trial of alternating weekly chemohormone therapy for patients with androgen independant prostate cancer. Clin Cancer Res 1997;3:2371-2376.
41. Hudes G, Roth B, Loehrer P et al. Phase III trial of vinblastine versus vinblastine plus estramustine phosphate for metastatic hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1997;16:316a.
42. Tannock IF, Osoba D, Stockier MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764.
43. Moore MJ, Osaba D, Murphy D et al. Use of palliative end points to evaluate the effects of mitoxantrone and low dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-694.
44. Osoba D, Tannock IF, Ernst AS et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-1663.
45. Shinohara N, Demura T, Matsumura K et al. 5-Fluorouracil and low dose recombinant interferon alpha-2a in patients with hormone refractory adenocarcinoma of the prostate. Prostate 1998;35:56-62.
46. Diener KM. Biphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 1996;53:1917-1927.
47. Dearnaley DP, Bayly RJ, A'Hern RP et al. Palliation of bone metastases in prostate cancer: hemibody irradiation or strontium 89? Clin Oncol 1992;4:101-107.
48. Tong D, Gullick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the radiation therapy oncology group. Cancer 1982;50:893.
49. Porter AT. Strontium 89 (Metastron) in the treatment of prostate cancer metastatic to bone. In: Murphy G, Khoury S, Chatelain A et al., eds. 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Paris, June 22-24, 1994:368-376.
50. Mertens W, Porter AT, Reid RH et al. Strontium 89 and low dose infusion cisplatinum for patients with hormone refractory prostate cancer metastatic to bone. J Nucl Med 1992;33:1437-1443.
51. Serarini AN, Houston J, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574-1581.
52. Didkman GA, Jauknegt RA, De Reijke TM et al. Long-term efficacy and safety of Nilutamide plus castration in advanced prostate cancer and significance of early PSA normalisation. International Anandron Study Group. J Urol 1997;158:160-163.
53. Thorpe SC, Azmatullah S, Fellow GJ et al. A prospective randomized study to compare gosereline acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastate prostatic carcinome. Eur Urol 1996;29:47-54.
54. Sartor O, Cooper M, Weinberger M et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatment of "hormone refractory" prostate cancer. J Natl Cancer Inst 1994;86:222-227.